GLP-1 Drugs: From Lab Discovery to Weight Loss Revolution

The story of GLP-1 drugs — now household names like Ozempic, Wegovy, and Mounjaro — is a tale of serendipity, decades of painstaking science, and a chance encounter with lizard venom. What began as a hunt for a better diabetes treatment has morphed into a global weight-loss revolution.

A Venomous Start

In the early 1990s, scientists at the Veterans Affairs Medical Center in the Bronx were studying a hormone called GLP-1. It was known to stimulate insulin release after meals. But GLP-1 degraded within minutes in the body — useless as a drug.

Enter the Gila monster. Researchers discovered a compound in its venom, exendin-4, which mimicked GLP-1 but lasted far longer. That synthetic version became Byetta, the first GLP-1 drug approved for diabetes in 2005.

Dr. John Eng, a researcher at the VA, first isolated the compound. His work, backed by the US Department of Veterans Affairs, laid the foundation for an entire class of drugs.

From Blood Sugar to Body Weight

Doctors prescribing Byetta noticed something odd. Patients were losing weight — not just a kilo or two, but significant amounts. The drug seemed to slow stomach emptying and signal the brain that the body was full.

This was not the primary goal. GLP-1 drugs were designed to manage blood sugar. But the weight loss effect was too pronounced to ignore.

Researchers at the University of Colorado Anschutz Medical Campus were among the first to study this phenomenon systematically. Dr. Daniel Bessesen and his team conducted clinical trials that showed sustained weight loss in patients using liraglutide, a longer-acting GLP-1 drug.

By 2014, liraglutide was approved for weight management under the brand name Saxenda. The market exploded.

The Ozempic Era

Novo Nordisk launched semaglutide — Ozempic for diabetes, Wegovy for weight loss — in 2017 and 2021 respectively. These drugs offered once-weekly injections and even greater weight loss, averaging 15% of body weight in trials.

Demand soared. Celebrities, influencers, and everyday patients rushed to get prescriptions. Shortages followed. The drugs became cultural shorthand for easy weight loss, sparking debates about body image and access.

But the science continued to evolve. Researchers at CU Anschutz and elsewhere are now studying whether GLP-1 drugs can treat addiction, heart disease, and even Alzheimer's. Early results are promising.

What's Next?

The next frontier is oral GLP-1 drugs. Novo Nordisk and Eli Lilly are developing pills that could replace injections. If successful, these would further widen access — and deepen the impact of a discovery that started with a lizard's bite.

How the story unfolds will depend on affordability, long-term safety data, and whether society can separate the drug from the hype. But one thing is clear: GLP-1 drugs are no longer just a treatment. They are a turning point.